Kunming Longjin Pharmaceutical Co., Ltd. has made significant advancements in the field of pharmaceutical technology, particularly in the development and production of traditional Chinese medicine. The company has established a cGMP Standard Solid Formulation Workshop and an innovative pilot-scale production platform, which enhances its manufacturing capabilities and ensures compliance with international quality standards. Additionally, Longjin has focused on the research and development of breviscapine, a key product derived from erigeron breviscapus, which has achieved GRAS certification from the FDA. This highlights the company's commitment to producing high-quality medicinal products that meet stringent regulatory requirements.

Moreover, Longjin has engaged in strategic collaborations with academic institutions, such as the School of Pharmacy at Kunming Medical University and Yunnan University, to foster innovation and talent development in the pharmaceutical sector. The establishment of subsidiaries, including Jiangsu Longjin Kangyou Biomedical Technology Co., Ltd., further supports its research initiatives and market expansion. The company has also been recognized for its contributions to the industry, receiving awards for its intellectual property and being listed among the top enterprises in Yunnan Province. These efforts underscore Longjin's dedication to advancing pharmaceutical technology and enhancing the efficacy of traditional Chinese medicine.

China

Kunming Longjin Pharmaceutical Co., Ltd. is a holding subsidiary of Yunnan CAS Longjin Biotechnology Co., Ltd. which serves as the polypeptide innovative drugs.

Kunming Longjin Pharmaceutical

Company Details